Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

Table 3

Sensitivity analysis.

	Number of studies	Results [95% CI]		Heterogeneity		Effect measure
		Fixed-effect model	Random-effect model	(%)	value
Response rate	18	1.55 [1.34, 1.79]	1.47 [1.28, 1.68]	0	0.80	Risk ratio
Disease control rate	18	1.28 [1.19, 1.37]	1.25 [1.15, 1.35]	29	0.12	Risk ratio
Overall survival	5	0.72 [0.61, 0.86]	0.70 [0.58, 0.86]	13	0.33	Hazard ratio
KPS	12	1.86 [1.53, 2.26]	1.74 [1.43, 2.12]	3	0.42	Risk ratio
Decline of leucocyte count	12	0.85 [0.79, 0.92]	0.85 [0.75, 0.97]	78	<0.00001	Risk ratio
VEGF	4	−1.32 [−1.59, −0.04]	−1.22 [−1.95, −0.48]	85	0.0002	SMD
Ratio of CD4/CD8	3	0.67 [0.38, 0.95]	0.70 [0.08, 1.33]	79	0.009	SMD